SCHEMBL4419863

SCHEMBL4419863

CCc1ccc(Oc2ccc(OC)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.56
IDO1 P14902 3/20 0.54
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 1/20 0.51
AGXT P21549 2/20 0.50
TAAR1 Q96RJ0 1/20 0.50
ALDH1A1 P00352 3/20 0.48
TP53 P04637 1/20 0.48
CYP3A4 P08684 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
ALOX12 P18054 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14380144 0.94 MAOB (0.55) LTA4HIDO1CA12CA1CA2
SCHEMBL30878 0.93 CA12 (0.61) LTA4HIDO1CA12CA1CA2
Ammonia Solution, Strong SCHEMBL266020 0.90 IDO1 (0.58) LTA4HIDO1CA12CA1CA2
Bromide SCHEMBL28187052 0.90 IDO1 (0.58) LTA4HIDO1CA12CA1CA2
SCHEMBL475215 0.90 SMN1; SMN2 (0.48) LTA4HSMN1; SMN2LMNATAAR1ALDH1A1
SCHEMBL8925998 0.90 SMN1; SMN2 (0.48) LTA4HSMN1; SMN2LMNATAAR1ALDH1A1
Bromide SCHEMBL25274321 0.88 IDO1 (0.56) LTA4HIDO1CA12CA1CA2
Ethyne SCHEMBL27462853 0.88 IDO1 (0.56) LTA4HIDO1CA12CA1CA2
Hydrochloric Acid SCHEMBL27637271 0.88 IDO1 (0.56) LTA4HIDO1CA12CA1CA2
SCHEMBL3799065 0.86 LTA4H (0.68) LTA4HIDO1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299354-B1 FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-22 EP claimed
EP-3841147-B1 AROMATIC POLYETHERS CONTAINING A BIOSOURCED FURAN DIOL ROQUETTE FRERES (FR) 2023-10-04 EP disclosed
WO-2018144900-A1 SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2018-08-09 WO disclosed
US-9782767-B2 Sulfonate-based compound and polymer electrolyte membrane using same LG CHEM, LTD. (KR) 2017-10-10 US disclosed
US-20150328630-A1 SULFONATE-BASED COMPOUND AND POLYMER ELECTROLYTE MEMBRANE USING SAME LG CHEM, LTD. (KR) 2015-11-19 US disclosed
US-20140363754-A1 POLYMER ELECTROLYTE COMPOSITION, ELECTROLYTE MEMBRANE, MEMBRANE-ELECTRODE ASSEMBLY AND FUEL CELL LG CHEM, LTD. (KR) 2014-12-11 US disclosed
US-7579479-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-25 US disclosed
EP-1299354-B1 FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-22 EP disclosed
US-7241780-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOLS-MYERS SQUIBB COMPANY (US) 2007-07-10 US disclosed
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T 2007-01-18 US disclosed
US-6743790-B2 A UREA OR THIOUREA DERIVATIVES CONTAINING AMIDE GROUP USEFUL AS ANTICOAGULANTS AND ANTIINFLAMMATORY AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-06-01 US disclosed
EP-1299354-A2 FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE Aventis Pharma Deutschland GmbH (DE) 2003-04-09 EP disclosed
WO-2001094301-A2 FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-12-13 WO disclosed
EP-1162194-A1 Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use Aventis Pharma Deutschland GmbH (DE) 2001-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150328630-A1 SULFONATE-BASED COMPOUND AND POLYMER ELECTROLYTE MEMBRANE USING SAME STOM, EPCAM, PTDSS2 LTA4H 3417/4885IDO1 4864/4885CA12 64/4885
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, ACACA LTA4H 3219/4885IDO1 3389/4885CA12 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.